← Dashboard
Aug 07, 2026 08:51 AM ET
Signal
FDA/Bio
Cognition Therapeutics Q2 Net Loss Narrows; Plans Phase 3 DLB Study Of Zervimesine In Mid 2027
Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027.
What changed
Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027.
Why it matters
Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →